CliffBio
small molecule

JULUCA

DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE

Loss of exclusivitySeptember 2038latest FDA-listed patent expiry
CompanyViiV Healthcare →See this company's full patent-cliff portfolio

Drug detail

Brand nameJULUCA
Active ingredientDOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE
StrengthEQ 50MG BASE;EQ 25MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalNovember 2017
Marketing statusRX

Listed patents

PatentExpiresType
12011506September 2038product
10426780January 2031substance, product
9242986*PEDJune 2030—
9242986December 2029substance, product
8129385*PEDApril 2028—
8129385October 2027substance, product

More from ViiV Healthcare

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.